Wyant G, Yu W, Doulamis I, Nomoto R, Saeed M, Duignan T, et al. Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists. Science. 2022;377:621-629 pubmed publisher

Rojewska E, Ciapała K, Mika J. Kynurenic acid and zaprinast diminished CXCL17-evoked pain-related behaviour and enhanced morphine analgesia in a mouse neuropathic pain model. Pharmacol Rep. 2019;71:139-148 pubmed publisher

Caltabiano G, Kent T, Jenkins L, McCallum J, Hudson B, Nicklin S, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014;85:91-104 pubmed publisher

Polcari A, Farooq A, Woods M, Ripsch M, Picken M, Turk T, et al. Effect of the phosphodiesterase-5 inhibitor zaprinast on ischemia-reperfusion injury in rats. J Endourol. 2013;27:338-42 pubmed publisher

Fox J, Sakamuru S, Huang R, Teneva N, Simmons S, Xia M, et al. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death. Proc Natl Acad Sci U S A. 2012;109:5423-8 pubmed publisher

Zerani M, Boiti C, Zampini D, Brecchia G, Dall Aglio C, Ceccarelli P, et al. Ob receptor in rabbit ovary and leptin in vitro regulation of corpora lutea. J Endocrinol. 2004;183:279-88 pubmed

Robichaud A, Savoie C, Stamatiou P, Lachance N, Jolicoeur P, Rasori R, et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol. 2002;135:113-8 pubmed